DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

Phase 1

Completed

Conditions: Cutaneous T Cell Lymphoma

Interventions: Drug: Topical resiquimod 0.06%
Drug: topical resiquimod 0.03%

First Posted Date: 2012-08-31

Last Posted Date: 2019-08-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 13

Registration Number: NCT01676831

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

HPPH and PDT for Pleural Malignancy

Phase 1

Completed

Conditions: Pleural Malignancy

First Posted Date: 2012-08-27

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 37

Registration Number: NCT01673074

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Phase 4

Completed

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Fesoterodine
Drug: Placebo oral tablet

First Posted Date: 2012-08-09

Last Posted Date: 2020-04-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3

Registration Number: NCT01661166

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Multi-peptide Vaccine With Basilixumab for Breast Cancer

Early Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: hTERT

First Posted Date: 2012-08-08

Last Posted Date: 2019-06-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01660529

Locations: 🇺🇸
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dovitinib in Neuroendocrine Tumors

Phase 2

Completed

Conditions: Advanced Metastatic Paraganglioma
Advanced Metastatic Pheochromocytoma
Recurrent Paraganglioma
Recurrent Pheochromocytoma
Unresectable Paraganglioma
Unresectable Pheochromocytoma

Interventions: Drug: Dovitinib

First Posted Date: 2012-07-10

Last Posted Date: 2020-04-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT01635907

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

CRLX101 Plus Bevacizumab in Advanced RCC

Phase 1

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2012-06-22

Last Posted Date: 2018-08-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT01625936

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Phase 2

Completed

Conditions: Estrogen-receptor Positive Invasive Metastatic Breast Cancer

Interventions: Drug: Ruxolitinib
Drug: Exemestane

First Posted Date: 2012-05-09

Last Posted Date: 2024-06-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT01594216

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Autophagy Induction After Bortezomib for Myeloma

Early Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib

First Posted Date: 2012-05-09

Last Posted Date: 2019-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 11

Registration Number: NCT01594242

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Radiation Oncology Registry and Biosample Repository

Recruiting

Conditions: Neoplasia

First Posted Date: 2012-04-13

Last Posted Date: 2025-02-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8000

Registration Number: NCT01577251

Locations: 🇺🇸
Virtua Samson Cancer Center, Moorestown, New Jersey, United States
🇺🇸
Virtua Health & Wellness Center, Voorhees, New Jersey, United States
🇺🇸
Lancaster General Hospital, Lancaster, Pennsylvania, United States

and more 1 locations

Maintenance Lenalidomide in Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2012-04-12

Last Posted Date: 2023-03-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT01575860

Locations: 🇺🇸
Jakub Svoboda, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy